Can You Survive on ONLY the $2,000/Month Emergency CRA Payments?

The Canopy Growth stock continues to underperform in 2020. About 1,000 employees have been laid off after three rounds of cuts. The displaced workers, along with thousands more, badly need the $2,000 monthly emergency CRA payments.

| More on:
Handwriting text writing Are You Ready For Tomorrow question. Concept meaning Preparation to the future Motivation Stand blackboard with white words behind blurry blue paper lobs woody floor.

Image source: Getty Images

Financial dislocation is the universal worry in the 2020 coronavirus outbreak. As businesses grind to a halt, companies are preserving balance sheets while workers are losing jobs. Without regular sources of income, people need temporary relief.

The Canada Emergency Relief Benefit (CERB) is Canada’s emergency measure. It provides $2,000 per month to the employed and self-employed as well as the underemployed. However, can one survive on just this amount being doled out through the Canada Revenue Agency (CRA)?

Taxable benefit

CERB serves as an income replacement benefit while lockdowns are in effect. The federal government is softening the economic blow of the deadly COVID-19 on working Canadians. The $500 per week for up to 16 weeks is meant to tide people over during the health crisis.

Recipients, however, must be aware of the catch. The CERB is taxable and taxpayers need to report this benefit next year when they file income tax returns for the year 2020.

If you receive the maximum CERB benefit of $8,000, the tax rate is 15% or $1,200 at tax time. Thus, the monthly CRA emergency payment is effectively only $6,800. The tax is not deducted upfront. One analyst advises recipients not to spend it all because you will owe the government taxes in 2021.

Displaced workers growing

Before the emergence of the novel coronavirus, the marijuana industry was already struggling. Industry leader Canopy Growth (TSX:WEED)(NYSE:CGC) was incurring massive losses to the detriment of major investor Constellation Brands.

This $8.27 billion cannabis producer is on its third round of employee layoffs. About 1,000 have been given the exit door. The firings were announced via a Zoom group call. The restructuring was the reason given for the layoffs.

The shares of Canopy Growth are among the most volatile in the current environment. WEED posted a 25.4% loss in 2019. As of this writing, the year-to-date loss is 13.4%, with the stock trading at $23.64 per share.

Canopy CEO David Klein has the daunting task of lowering the company’s cost structure while reducing the cash burn at the same time. Apart from the layoffs, there was a multi-million write-down and closures of greenhouses.

In this quarantine era, sales of CBD edibles (+28%) and cannabis-infused beverages (+14%) are rising. Canopy Growth is pursuing the cannabis beverage market that is estimated to be worth US$2.8 billion by 2025.

Still, Canopy Growth is facing profitability challenges. According to a Forbes report, its annual pot sales must be around $3 billion for the company to stay afloat.

Survival mode

The financial sting of the coronavirus is starting to deepen on workers, including the laid-off staff at Canopy Growth. Millions have applied for emergency benefit.

People are in survival mode. It would be difficult to make ends meet with only $2,000, especially with rent and other bills to pay. For those who are renting, the CERB is a minimal supplement.

Overall, the monthly emergency payment will not go far enough. However, the case for a universal basic income is getting stronger, with many Canadians experiencing economic shocks in the present health crisis.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Constellation Brands.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »